Loading…

Bruker CorporationBRKRCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of scientific instruments (mass spectrometry, NMR, X-ray) for life-science research, applied and clinical microbiology markets.

Momentum leader 90
Mkt cap
$9.66B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$157M
20-day average traded
Fwd P/E
27.0×
forward earnings
ROIC−WACC
-3.4 pp
WACC 10.5%
Hurdle
+14 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · USD$63.26
1D+3.1%
1W+1.4%
1M+13.1%
3M+5.6%
6M+42.9%
YTD+34.3%
1Y+51.5%
ATR %5.7%
Beta1.65
52w lowhigh8.3% off high

What Bruker does

Maker of scientific instruments (mass spectrometry, NMR, X-ray) for life-science research, applied and clinical microbiology markets.

Sells high-priced laboratory instruments to universities, government labs, drugmakers and hospitals, then earns repeat income from service contracts, upgrades and consumables on the installed base. Orders depend on research budgets, notably public research funding at universities. It has expanded into spatial biology and diagnostics through acquisitions, including NanoString in 2024.

Products and services

  • BioSpin (NMR/MRI research instruments)
  • CALID (mass spectrometry, clinical microbiology)
  • Nano (X-ray, atomic force microscopy)

Customers

  • Academic/government research labs
  • Pharma/biotech companies
  • Clinical microbiology labs

Where it sits in the supply chain

  • Healthcare/Life Sciences
  • Scientific instruments
  • Mass spec, NMR, microbiology…

What could go right

  • Proteomics/spatial biology research demand
  • Clinical microbiology testing growth

What could go wrong

  • Academic/government research funding cycle sensitivity
  • China market exposure

Moat: narrow (installed base, switching costs, IP / patents). Specialized, technically differentiated instruments with an installed base among research and clinical microbiology labs.

Headquarters: Billerica, Massachusetts, USA · Founded: 1960 · Employees: 11,085

Named competitors

Bruker at a glance

Size Bruker (BRKR) is a United States Health Care company (Medical Specialties) with a market value of $9.66B, the 790th largest of 3,085 United States companies the cockpit tracks. Shares closed at $63.26 on 18 Nov 2026.

Performance Over six months the shares gained 42.9%, against +25.4% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 2.2% over the last twelve months (peer median +7.2%); the operating margin is 10.1% (peer median 16.1%).

Valuation It trades at 27.0× forward earnings against a peer median of 19.9× (6th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.4 points below its cost of capital (10.5% WACC).

Backlog Backlog (remaining performance obligations) was $2.78B at 30 Sep 2026, up 34% on a year earlier — 0.8 years of trailing revenue. Backlog detail →

Short interest Short interest is 7.4% of the free float (30 Oct 2026).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026BRKR 141Peer median 125
Six months, rebased to 100: Bruker against the median of its 20 peers (local-currency closes).

Bruker financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.51B$3.44B$3.37B$2.96B$2.53B
Revenue growth—+2%+14%+17%—
Gross profit$1.69B$1.64B$1.66B$1.52B$1.31B
EBITDA$582M$500M$564M$597M$548M
Net income-$123M-$8.60M$113M$427M$297M
Free cash flow$245M$43.3M$136M$243M$145M
Capital expenditure$97.1M$90.8M$115M$107M$129M
Total debt$1.71B$2.04B$2.25B$1.38B$1.27B

Quarterly statements and history in the cockpit →

Bruker competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%+20%PODDGMEDBIOQGENDEMANTAVTR7701COOALGN6869BIM300832GETI-BBLCOSNPEN77337747BAXLENSKARTBRKR6-month return →1-month return →
Up and to the right = strong over both horizons. Bruker is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×PODDGMEDBIOQGENDEMANTAVTR7701COOALGN6869BIM300832GETI-BBLCOPEN77337747LENSKARTBRKRRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bruker is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%PODDGMEDBIOQGENDEMANTAVTR7701COOALGN6869BIM300832GETI-BSNPEN77337747BAXLENSKARTBRKRGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bruker is the large dot.

Bruker competitors and peer comparison

Head to head with its named competitors (BRKR vs TMO vs A vs WAT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bruker BRKR$9.66B+43%+2%10%27.0×25.4%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Agilent Technologies A$50.0B+56%+9%24%27.0×23.3%
Waters WAT$45.8B+37%+81%10%29.1×48.1%

How Bruker compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bruker against its 20 peers (data as of 18 Nov 2026)
MeasureBRKRPeer medianRank in peer set
1-month return+13.1%+5.0%6th highest of 21
6-month return+42.9%+25.4%4th highest of 21
Distance from 52-week high-8.3%-11.7%9th highest of 21
Revenue growth (TTM)+2.2%+7.2%5th lowest of 21
Operating margin10.1%16.1%6th lowest of 21
Forward P/E27.0×19.9×6th most expensive of 21
Growth the price implies (Req g, 7 yrs)25.4%10.0%4th most demanding of 21
Growth delivered (Del g)+11.6%+9.9%7th highest of 21
Hurdle (Req g minus delivered)+13.8 pp+1.9 pp5th most demanding of 21
ROIC minus cost of capital-3.4 pp+2.5 pp3rd lowest of 21
EV / EBITDA19.3×12.7×4th most expensive of 20
Net debt / EBITDA2.7×0.5×5th most indebted of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%

Bruker backlog

Bruker reported $2.78B of remaining performance obligations at 30 Sep 2026, up 34% from a year earlier and flat from the previous quarter. That is 0.8 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Bruker's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Agilent Technologies (A), Waters Corporation (WAT). The cockpit's measured peer set (industry) also includes Insulet (PODD), Globus Medical (GMED), Bio-Rad Laboratories (BIO), Qiagen (QGEN), Demant A/S (DEMANT.CO), Avantor (AVTR).
Is Bruker expensive compared with its peers?
On forward p/e it trades at 27.0× against a peer median of 19.9×, 6th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Bruker stock performed?
Over six months to 18 Nov 2026 the shares returned +42.9% against +25.4% for the median peer; over one year +51.5%.
What is Bruker's backlog?
Bruker's remaining performance obligations (contracted revenue not yet recognised) were $2.78B at 30 Sep 2026, +34% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.